{
    "nctId": "NCT05132101",
    "briefTitle": "Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea",
    "officialTitle": "Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a 1st Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Total treatment duration and cycle for Palbociclib",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who were prescribed with palbociclib in combination with AI for at least 1 cycle during the index period\n* Patients who were diagnosed with BC during the index period\n\nExclusion Criteria:\n\n* Male\n* Prescribed with palbociclib during 12-month period preceding the index date",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}